JCM
CPRX

JS Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

JS Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-16,000
Closed -$60K – 141
2019
Q4 		$60K Buy
+16,000
New +$74.8K 0.01% 119

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

JS Capital Management's CPRX Position: Q1 2020 in Review

JS Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2020, closing a stake of 16,000 shares — an estimated $60K sold.

JS Capital Management first reported a position in CPRX in Q4 2019 and held it in 1 quarter. The position peaked at $60K in Q4 2019. 131 funds tracked by Wall St. Rank hold CPRX as of Q1 2020.

  • JS Capital Management reported no remaining Catalyst Pharmaceutical position as of Q1 2020 after selling out during the quarter.
  • JS Capital Management sold 16,000 Catalyst Pharmaceutical shares in Q1 2020, an estimated $60K.
  • JS Capital Management first reported a position in Catalyst Pharmaceutical in Q4 2019 and held it in 1 quarter.
  • JS Capital Management's Catalyst Pharmaceutical position peaked at $60K in Q4 2019.
  • 131 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2020.

Based on JS Capital Management's 13F filing for Q1 2020, filed 15 May 2020.